Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: Focus on ibrutinib

Therapeutic Advances in Hematology

Volumn 5, Issue 4, 2014, Pages 121-133

  Aalipour, Amin ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B cell receptor signaling; Bruton's tyrosine kinase; chronic lymphocytic leukemia; ibrutinib; mantle cell lymphoma; refractory non Hodgkin's lymphoma

Indexed keywords

EID: 84993705076     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714539906     Document Type: Review

References (71)

1. Aalipour A. Advani R. (2013) Bruton tyrosine kinase inhibitors: a promising novel targeting treatment for B cell lymphomas. Br J Haematol 163: 436–443.
2. Advani R. Buggy J. Sharman J. Smith S. Boyd T. Grant B. et al. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed / refractory B-cell malignancies. J Clin Oncol 31: 88–94.
3. Akinleye A. Chen Y. Mukhi N. Song Y. Liu D. (2013) Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 6: 59.
4. Amrein P. Attar E. Takvorian T. Hochberg E. Ballen K. Leahy K. et al. (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17: 2977–2986.
5. Ansell S. (2013) Two targets for the price of one. Blood 122: 2529–2531
6. Axelrod M. Ou Z. Brett L. Zhang L. Lopez E. Tamayo A. et al. (2014) Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia 28: 407–410.
7. Barrientos J. Rai K. (2013) Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54: 1817–1820.
8. Bhatt V. Alejandro L. Michael A. Ganetsky A. (2014) The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy 34: 303–314.
9. Brown J. (2014) Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma 55: 263–268.
10. Brown J. Barrientos J. Barr P. Flinn I. Burger J. Salmon Z. et al. (2013 a) Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed / refractory CLL/SLL: final results of a phase 1b study [abstract]. Blood 122: 525.
11. Brown J. Harb W. Hill B. Gabrilove J. Sharman J. Schreeder M. (2013 b) Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed / refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood 122, 1630.
12. Brown J. Harb W. Sharman J. Hill B. Ma S. Miller T. et al. (2013 c) Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (Btk) inhibitor, in relapsed / refractory chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (b-NHL) [abstract]. 18th Annual Congress of the European Hematology Association, 13–16 June, Stockholm, Sweden.
13. Burger J. (2014) Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 9: 44–49.
14. Burger J. Buggy J. (2013) Emerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54: 2385–2391.
15. Burger J. Keating M. Wierda W. Hoellenriegel J. Jeyakumar G. Ferrajoli A. et al. (2013) Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase ii trial in 40 patients [abstract]. Blood 122: 675.
16. Byrd J. Furman R. Coutre S. Flinn I. Burger J. Blum K. et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32–42.
17. Cao Y. Hunter Z. Liu X. Xu L. Yang G. Tripsas C. et al. (2013) Somatic activating mutations in CXCR 4 are common in patients with Waldenström's macroglobulinemia, and their expression in WM cells promotes resistance to ibrutinib [abstract]. Blood 122: 4424.
18. Chen L. Monti S. Juszczynski P. Daley J. Chen W. Witzig T. et al. (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111: 2230–2237.
19. Cheng S. Ma J. Guo A. Lu P. Leonard J. Coleman M. et al. (2014) BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28: 649–657.
20. Cinar M. Hamedani F. Mo Z. Cinar B. Amin H. Alkan S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res 37: 1271–1277.
21. Dal Porto J. Gauld S. Merrell K. Mills D. Pugh-Bernard A. Cambier J. (2004) B cell antigen receptor signaling 101. Mol Immunol 41: 599–613.
22. Dasmahapatra G. Patel H. Dent P. Fisher R. Friedberg J. Grant S. et al. (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161: 43–56.
23. Davids M. Brown J. (2012) Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 53: 2362–2370.
24. Davis R. Ngo V. Lenz G. Tolar P. Young R. Romesser P. et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88–92.
25. de Rooij M. Kuil A. Geest C. Eldering E. Chang B. Buggy J. et al. (2012) The clinical active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine- controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119: 2590–2594.
26. Dominici E. Lopez E. Vang M. Tamayo A. Ou Z. Rollo A. et al. (2013) Carfilzomib, a second-generation proteasome inhibitor, in combination with the Btk inhibitor ibrutinib as a novel therapeutic regimen for treating double hit DLBCL [abstract]. Blood 122: 1834.
27. Dubovsky J. Beckwith K. Natarajan G. Woyach J. Jaglowski S. Zhong Y. et al. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122: 2539–2549.
28. Dühren-von Minden M. Übelhart R. Schneider D. Wossning T. Bach M. Buchner M. et al. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489: 309–312.
29. Evans E. Aslanian S. Karp R. Sheets M. Chaturvedi P. Mazdiyasni H. et al. (2011 a) Bruton's tyrosine kinase from bench to bedside: covalently silencing B cells with AVL-292. 11th Annual Meeting of the Federation of Clinical Immunology Societies, 23–26 June, Washington DC, USA.
30. Evans E. Tester R. Aslanian S. Chaturvedi P. Mazdiyasni H. Ponader S. et al. (2011 b) Clinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies [abstract]. Blood 118: 3485.
31. Evans E. Tester R. Aslanian S. Karp R. Sheets M. Labenski M. et al. (2013) Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 346: 219–228.
32. Farooqui M. Aue G. Valdez J. Martyr S. Jones J. Soto S. et al. (2013) Single agent ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p [abstract]. Blood 122: 673.
33. Fowler N. Advani R. Sharman J. Smith S. McGreivy J. Kunkel L. et al. (2012) The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [abstract]. Blood 120: 156.
34. Garraway L. Jänne P. (2012) Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2: 214–226.
35. Herman S. Gordon A. Hertlein E. Ramanunni A. Zhang X. Jaglowski S. et al. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117: 6287–6296.
36. Honigberg L. Smith A. Sirisawad M. Verner E. Loury D. Chang B. et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107: 13075–13080.
37. Improgo R. Tiao G. Kiezun A. Wang Y. Werner L. Sougnez C. et al. (2013) NF-κB pathway mutations modulate cell survival and ibrutinib response in chronic lymphocytic leukemia [abstract]. Blood 122: 670.
38. Jaglowski S. Jones J. Flynn J. Andritsos L. Maddocks K. Blum K. et al. (2012) A phase Ib / II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) and related diseases [abstract]. J Clin Oncol 30: 6508.
39. Jain N. O'Brien S. (2013) Ibrutinib (PCI-32765) in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 27: 851–860.
40. Kharfan-Dabaja M. Wierda W. Cooper L. (2013) Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 28: 507–517.
41. Kohrt H. Sagiv-Barfi I. Rafiq S. Herman S. Butchar J. Cheney C. (2013) Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity [abstract]. Blood 122: 373.
42. Kozaki R. Yoshizawa T. Tohda S. Yasuhiro T. Hotta S. Ariza Y. et al. (2011) Development of a Bruton's tyrosine kinase (Btk) inhibitor, ONO-WG-307: efficacy in ABC-DLBCL xenograft model – potential treatment for B-cell malignancies [abstract]. Blood 118: 3731.
43. Kozaki R. Yoshizawa T. Yashuhiro T. Mirjolet J. Birkett J. Narita M. et al. (2012) Development of a Bruton's tyrosine kinase (Btk) inhibitor – ONO-WG-307, a potential treatment for B-cell malignancies [abstract]. Cancer Res 72: 857.
44. Maas A. Hendriks R. (2001) Role of Bruton's tyrosine kinase in B cell development. Dev Immunol 8: 171–181.
45. Mahajan S. Ghosh S. Sudbeck E. Zheng Y. Downs S. Hupke M. et al. (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 274: 9587–9599.
46. Monroe J. (2006) ITAM-mediated tonic signaling through pre-BCR and BCR complexes. Nat Rev Immunol 6: 283–294.
47. Ngo V. Young R. Schmitz R. Jhavar S. Xiao W. Lim K. et al. (2011) Oncogenically active MYD 88 mutations in human lymphoma. Nature 470: 115–119.
48. O'Brien S. Furman R. Coutre S. Sharman J. Burger J. Blum K. et al. (2014) Ibrutinib as an initial therapy for elderly patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15: 48–58.
49. O'Brien S. Furman R. Fowler N. Coutre S. Sharman J. Blum K. et al. (2013) The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study [abstract]. Blood 122: 4163.
50. Ou Z. Pham L. Vang M. Zhang L. Wang J. Strickland L. et al. (2013) Targeting BCR activated STAT 3 by ibrutinib in mantle cell lymphoma [abstract]. Blood 122: 3079.
51. Pharmacyclics, Inc. (2014) Independent data monitoring committee recommends phase III study of IMBRUVICATM (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival. Press release. Sunnyvale, CA, USA.
52. Pierce D. Ponader S. Balakrishnan K. Gandhi V. Wierda W. O'Brien S. et al. (2013) Target engagement, pathway inhibition, and efficacy of the Bruton's tyrosine kinase (Btk) inhibitor CC-292 [abstract]. Blood 122: 4169.
53. Ponader S. Chen S. Buggy J. Balakrishnan K. Gandhi V. Wierda W. et al. (2012) Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119: 1182–1189.
54. Rinaldi A. Kwee I. Taborelli M. Largo C. Uccella S. Martin V. et al. (2006) Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 132: 303–316.
55. Robak T. Robak P. (2013) BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 32: 358–376.
56. Rule S. Shah N. Salles G. Karlin L. Morschhauser F. Terriou L. et al. (2013) A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed / refractory B-cell lymphoma [abstract]. Blood 122: 4397.
57. Salles G. Karlin L. Rule S. Shah N. Morschhauser F. Terriou L. et al. (2013) A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed / refractory and high risk chronic lymphocytic leukaemia (CLL) [abstract]. Blood 122: 676.
58. Tesar B. Klitgaard J. Chaudhary D. Werner L. Improgo R. Pochet N. et al. (2013) Effect of MYD 88 mutation in CLL on IRAK 4 and BTK inhibition in vitro [abstract]. Blood 122: 4132.
59. Treon S. Tripsas C. Yang G. Cao Y. Xu L. Hunter Z. et al. (2013) A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenström's macroglobulinemia [abstract]. Blood 122: 251.
60. Uckun F. Dibirdik I. Sarkissian A. Qazi S. (2011) In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors. Arzneimittel-Forschung 61: 252–259.
61. Uckun F. Zheng Y. Cetkovic-Cvrlje M. Vassilev A. Lisowski E. Waurzyniak B. et al. (2002) In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 8: 1224–1233.
62. Wang M. Rule S. Martin P. Goy A. Auer R. Kahl B. et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516.
63. Wiestner A. (2012) Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood 120: 4684–4691.
64. Wiestner A. (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31: 128–130.
65. William B. Hohenstein M. Loberiza Jr F. Caponetti G. Bociek R. Bierman P. et al. (2010) Phase I / II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) [abstract]. Blood 116: 288.
66. Wilson W. Gerecitano J. Goy A. de Vos S. Kenkre V. Barr P. et al. (2012) The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed / refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood 120: 686.
67. Yang G. Zhou Y. Liu X. Xu L. Cao Y. Manning R. et al. (2013) A mutation in MYD 88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122: 1222–1232.
68. Yasuhiro T. Yoshizawa T. Daub H. Weber C. Narita M. Kawabata K. (2012) ONO-WG-307, a novel, potent and selective inhibitor of Bruton's tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathways [abstract]. Cancer Res 72: 2012.
69. Younes A. Flinn I. Berdeja J. Friedberg J. Casulo C. Thieblemont C. et al. (2013) Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 122: 852.
70. Zhang L. Ou Z. Wang J. Dominici E. Zhang H. Ford R. et al. (2013) Ibrutinib overcomes carfilzomib resistance in immunoproteasome-deficient mantle cell lymphoma [abstract]. Blood 122: 3074.
71. Zhao X. Bodo J. Sun D. Lin J. Durkin L. Shetty S. et al. (2013) Combination of ibrutinib with ABT-199, a BCL-2 pathway inhibitor: effective therapeutic strategy in a novel mantle cell lymphoma cell line model [abstract]. Blood 122: 645.